Pfizer filed a lawsuit against fellow pharmaceutical giant Johnson & Johnson (J&J) over “anticompetitive practices” in a go-for-the-throat showdown involving the drug industry’s treatment of medicines that are similar to the originals, but don’t have the same exact active components.
Pfizer accused J&J of “exclusionary contracts” and price manipulation “to maintain its monopoly” for a drug used to treat rheumatoid arthritis, Crohn’s disease and other afflictions.
The brawl between Pfizer and J&J centers on the competition between J&J’s Remicade and Pfizer’s biosimilar alternative, Inflectra, which launched in late 2016.
Pfizer alleged that J&J threatened to withhold rebates from insurers that had determined Inflectra was an acceptable medical alternative to Remicade. The threats, Pfizer alleged, caused insurers to reverse course.
J&J also offered discounts on Remicade to healthcare providers in exchange for their pledge not to carry Inflectra, Pfizer alleged.
“These anticompetitive practices are preventing physicians from trying and patients from accessing the biosimilar,” Pfizer said in a statement.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Probes Lindab’s Acquisition of HAS-Vent Amid Fears of Market Monopoly
Apr 28, 2024 by
CPI
Shein Faces EU Regulations Over User Data
Apr 28, 2024 by
CPI
Google Fights Back Against US Antitrust Lawsuit
Apr 28, 2024 by
CPI
US Homeland Security Establishes Blue-Ribbon Board with Tech CEOs to Advise on AI
Apr 28, 2024 by
CPI
FTC Accuses Amazon Executives of Using Disappearing Messaging Apps to Conceal Evidence
Apr 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI